News
Oct 7, 2026

Trinity Study Finds PrEP Drug Causes Alteration of Immune Cells

Evelyn San MiguelSTAFF WRITER
blank
Image via Creative Commons

A new study in conjunction with researchers from Trinity Translational Medicine Institute (TTMI) and clinicians at St. James Hospital revealed new findings on the ways in which Pre-Exposure Prophylaxis (PrEP) drugs used to treat HIV can alter the functions of the immune system. Working with gay and bisexual men receiving PrEP treatment at St. James Hospital, patients were followed longitudinally over the span of six to nine months. Researchers studied how each patient’s immune system responded to the medication, examining for any negative side effects or symptoms and how those might be indicative of specific immune responses. The study revealed previously unrecognised impacts of antiretroviral drugs like PrEP on the immune system, highlighting the fact that preventative medications like these also have an effect on the immune system in spite of lack of an infection.

Over time PrEP changes the structure of monocytes, a kind of white blood cell that fights viruses like HIV and acts as a first responder when viruses initially enter the body. PrEP also impacts the metabolism of immune cells, increasing the amount of white blood cells that are released to fight potential infection.

Drugs like PrEP have changed HIV from a terminal illness to a manageable chronic condition. Despite gains made in lifespan, the health span of those living with HIV or on long-term antiretroviral medications like PrEP are still significantly worse than those who are HIV-negative. Cardiovascular conditions like heart disease are much more prevalent in people taking long-term anti-retrovirals like PrEP, as well as inflammatory conditions that can affect various organs of the body over time.

ADVERTISEMENT

Research on HIV’s impact on the immune system is usually very difficult, as the presence of HIV in the body can prevent researchers from knowing which responses can be attributed to HIV or to the side effects of a Post-Exposure Prophylaxis (PeP) drug. “We chose to study the cohort of men who were taking PrEP because they’re a way to study the effect of anti-retrovirals in the absence of [HIV]”, Dr. Sharee Basdeo said. As Deputy Director at TTMI and senior author of the study alongside clinician Dr. Liam Townshend, Dr. Basdeo specializes in immunology and the translation of scientific research into quantifiable medicine and patient impact.

In studying and researching the innate immune cell response under PrEP, Dr. Basdeo and her fellow researchers hope to improve not only the lifespan of those living with HIV and those on PrEP, but also their long-term health. “If you can fine tune what the mechanism is, you’ll be able to target it; to stop it, or promote it”, Dr. Basdeo affirmed.

The study not only poses new developments in increasing the lives and health of those taking PrEP and who are HIV-positive, but also tackles the challenge of tuberculosis infection in those living with HIV. Currently tuberculosis is the leading cause of death in those who test positive for HIV, both of which are most unlikely to have access to effective treatment in much of the global south, including World Health Organisation (WHO) regions of South-East Asia, the Western Pacific, and Africa.

White blood cells taken from patients were stimulated with tuberculosis in order to witness the response in comparison to subjects on PrEP to those not on PrEP. Over time the risk factor for tuberculosis came down slightly with the presence of PrEP, but still not down to a baseline that might be found in those who are HIV-negative. Over the course of research, it became clear that there is still immune vulnerability making HIV-positive patients more susceptible to tuberculosis even with the presence of PrEP treatment.

Dr. Basdeo noted the importance of observing the anti-retroviral’s effect on the tuberculosis cells. As avenues for research open, Dr. Basdeo hopes to see further developments in reducing the impact of bacterial infections like tuberculosis in patients with conditions that make them immunocompromised like being HIV-positive.

Sign Up to Our Weekly Newsletters

Get The University Times into your inbox twice a week.